Arpida Press Release Archive 2007-2009

Reinach, Switzerland, 26 November 2009. The Extraordinary General Meeting of Arpida Ltd (SIX: ARPN) has approved the proposals that were put forward by the Board of Directors.

ARPIDA SHAREHOLDERS’ MEETING TO TAKE PLACE ON 26 NOVEMBER 2009 Reinach, Switzerland, 4 November 2009. Arpida Ltd. (SIX: ARPN) today announced that it has entered into a definitive agreement to combine its business with that of Evolva SA. The combination agreement sets out the details of the proposed transaction and has been approved by the Boards of Directors of both companies and by investors, holding a majority of Evolva AG’s shares. In addition, independent valuation experts assessed Evolva SA’s business activities and concluded that the value, attributed to Evolva’s contribution in the proposed merger, fairly reflects its market value.

Reinach/Allschwil, Switzerland, 10 September 2009. Arpida Ltd. (“Arpida”) and Evolva SA (“Evolva”), two Swiss biotech companies, today announced that they intend to merge the two companies subject to definitive agreement and shareholder approval. Arpida is listed on the Swiss stock exchange (SIX Swiss Exchange: ARPN) while Evolva is a privately-held company with headquarters near Basel and operations in Denmark, USA and India. The intended merger creates a company with promising growth prospects based on a pipeline of clearly differentiated drug candidates addressing major medical needs and a number of discovery partnerships generating significant revenues.

Reinach, Switzerland, 7 May 2009. The Annual General Meeting of Arpida Ltd (SIX: ARPN) has approved the proposals that were put forward by the Board of Directors. A total of 90 shareholders were present at the meeting that took place in Reinach today. 4,629,711 shares were represented, or 21.9% of the total number of shares issued (21,094,104).